OncoMatch/Clinical Trials/NCT05717712
Oncolytic Virus Ad-TD-nsIL12 for Primary Pediatric Diffuse Intrinsic Pontine Glioma
Is NCT05717712 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies Ad-TD-nsIL12 for oncolytic virus.
Treatment: Ad-TD-nsIL12 — This is a drug safety assessment clinical trial with a 3+3 dose escalation design, to observe the safety, tolerability and toxicity of a novel oncolytic virus Ad-TD-nsIL12 intratumoral injection in primary DIPG patients (NCI-CTCAE V5.0).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Diffuse Intrinsic Pontine Glioma
Demographics
Prior therapy
Cannot have received: investigational medication
Other investigational medications within 30 days prior to viral treatment
Cannot have received: vaccine
Administer any type of vaccine within 30 days prior to Ad-TD-nsIL12 administration
Cannot have received: blood transfusion or drugs (such as G-CSF) to treat pancytopenia or other blood disorders
Blood transfusions or drugs (such as G-CSF) within 28 days before baseline to treat pancytopenia or other blood disorders
Lab requirements
Blood counts
Neutrophils ≥ 1x10^9/L; Platelets > 100x10^9/L; Hemoglobin ≥ 9 g/dl; No severe bone marrow failure or hypoplasia
Kidney function
No severe renal failure
Liver function
Transaminases (AST and/or ALT) or total bilirubin ≤ 3 times the upper limit of normal
Cardiac function
No heart failure
Serious infections or intercurrent conditions, including but not limited to severe renal failure, liver failure, heart failure, or bone marrow failure, which are not permitted for inclusion according to the investigator's criteria. Transaminases (AST and/or ALT) or total bilirubin > 3 times the upper limit of normal [excluded]. Neutrophils < 1x10^9/L. Platelets ≤ 100x10^9/L. Hemoglobin < 9 g/dl. Severe bone marrow hypoplasia.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05717712 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Is there an age limit?
Yes. Patients must be 18 years or younger and at least 1 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages